```html

Yamada Disease (Idiopathic Sclerosing Mesenteritis)

Overview

Yamada disease, more commonly referred to in the medical literature as idiopathic sclerosing mesenteritis (ISM), is a rare inflammatory and fibrotic disorder that involves the adipose tissue of the mesentery—the membrane that attaches the small intestine to the posterior abdominal wall. The disease is characterized by a spectrum that ranges from primarily inflammatory (mesenteric panniculitis) to fibrotic (retractile mesenteritis) patterns, and many patients exhibit features of both.

• Typical age of onset: 50–70 years, with a peak around 60 years.
• Gender distribution: Slight male predominance (≈ 55 % men, 45 % women).
• Prevalence: Exact prevalence is unknown because many cases are asymptomatic, but incidental findings on computed tomography (CT) scans suggest a prevalence of 0.6–2.5 % in the general adult population [1][2].
• Geographic variation: No clear regional clustering; cases have been reported worldwide.

The eponym “Yamada disease” stems from early case series by Japanese gastroenterologists who first described the condition in the 1970s. Modern terminology favors “idiopathic sclerosing mesenteritis” because the exact cause remains unknown.

Symptoms

Symptoms are highly variable; up to 30 % of individuals are completely asymptomatic and are diagnosed incidentally. When symptoms occur, they tend to be nonspecific and can mimic other intra‑abdominal conditions.

Symptom	Description
Abdominal pain	Often vague, dull, or cramp‑like in the mid‑abdominal or left upper quadrant. Pain may be intermittent and worsens after meals.
Weight loss	Unintentional loss of 5–10 % body weight over months, usually due to reduced appetite and early satiety.
Altered bowel habits	Diarrhea, constipation, or alternating patterns; sometimes a sensation of incomplete evacuation.
Nausea / vomiting	More common when the inflamed mesentery causes partial obstruction.
Abdominal mass	Palpable firm area in the left abdomen; may be mistaken for a tumor.
Fever or chills	Low‑grade fever (≤38 °C) in the inflammatory phase; present in ~10 % of cases.
Fatigue	Generalized tiredness secondary to chronic inflammation.
Obstructive symptoms	Signs of small‑bowel obstruction—abdominal distention, high‑pitched bowel sounds, inability to pass flatus or stool.

Causes and Risk Factors

The term “idiopathic” reflects the fact that no single cause has been definitively proven. Several associations have been observed, suggesting that ISM may be a final common pathway of diverse insults.

Proposed mechanisms

• Autoimmune/inflammatory reaction: Histologic studies show lymphoplasmacytic infiltrates, suggesting an immune‑mediated process [3].
• Prior abdominal surgery or trauma: Mechanical irritation may trigger chronic inflammation; up to 40 % of reported cases had previous surgeries [4].
• Infection: Rare links to hepatitis C, tuberculosis, and bacterial peritonitis have been described, but causal relationships remain uncertain.
• Ischemia: Small‑vessel mesenteric ischemia may initiate fibrosis.
• Neoplastic association: Concurrent lymphoma, pancreatic adenocarcinoma, or carcinoid tumors have been reported; ISM may be a paraneoplastic phenomenon in <5 % of cases [5].

Risk factors

• Middle‑aged to older adults (≥ 50 y)
• Male gender (modest increase)
• History of abdominal surgery (e.g., cholecystectomy, hernia repair)
• Autoimmune disorders (e.g., rheumatoid arthritis, systemic lupus erythematosus)
• Chronic alcohol use (possible link via pancreatic disease)
• Smoking (vascular and inflammatory effects)

Diagnosis

Because symptoms are nonspecific, diagnosis relies heavily on imaging and, when necessary, tissue sampling to exclude malignancy.

Imaging studies

• Contrast‑enhanced CT scan (most widely used): Classic “misty mesentery” appearance—soft‑tissue attenuation in the mesenteric fat, a preserved fat halo around mesenteric vessels (the “fat‑ring sign”), and sometimes calcifications. Sensitivity > 90 % for detecting mesenteric inflammation [6].
• MRI: Provides superior soft‑tissue contrast; useful when radiation exposure is a concern. T1‑weighted images show low signal intensity; T2 may show variable hyperintensity depending on inflammation vs. fibrosis.
• Positron emission tomography (PET): FDG‑PET can differentiate active inflammation (high uptake) from fibrotic, inactive disease and helps rule out malignancy.

Laboratory tests

• Complete blood count – may reveal mild anemia or leukocytosis.
• Inflammatory markers – elevated ESR or CRP in the inflammatory phase.
• Autoimmune panel – to identify associated conditions (ANA, RF).
• Serum IgG4 – elevated in a minority of cases, suggesting IgG4‑related disease.

Histopathology

When imaging is equivocal or malignancy cannot be excluded, image‑guided core needle biopsy or laparoscopic excisional biopsy is performed. Histologic hallmarks include:

• Fat necrosis.
• Lymphoplasmacytic infiltrate with occasional eosinophils.
• Fibrosis ranging from mild to dense “retractile” layers.
• Absence of malignant cells.

Diagnostic criteria (proposed)

1. Radiologic evidence of mesenteric soft‑tissue mass with fat‑ring sign.
2. Exclusion of neoplastic, infectious, or vascular causes (via imaging, labs, or biopsy).
3. Clinical presentation compatible with ISM (e.g., abdominal pain, weight loss).

Treatment Options

There is no universally accepted treatment algorithm; management is individualized based on disease severity, symptom burden, and dominant pathology (inflammatory vs. fibrotic).

Pharmacologic therapy

• Corticosteroids: Prednisone 40–60 mg daily for 2–4 weeks, followed by a taper, is often first‑line for symptomatic inflammatory disease. Response rates of 60–70 % have been reported [7].
• Immunosuppressants: Azathioprine (2 mg/kg/day) or mycophenolate mofetil can be used as steroid‑sparing agents, especially for chronic disease.
• Colchicine: 0.6 mg twice daily; useful for patients with mild inflammation and good tolerance.
• Tamoxifen: 20 mg twice daily; has antifibrotic properties and has shown benefit in retrospective series.
• Biologic agents: Small case reports describe successful use of TNF‑α inhibitors (infliximab, adalimumab) and rituximab in refractory cases, but data are limited.

Procedural interventions

• Endoscopic or percutaneous drainage: For large, symptomatic fluid collections or cystic components.
• Stent placement: If the mesenteric fibrosis causes duodenal or bowel obstruction, endoscopic stenting may relieve symptoms.
• Surgical resection: Reserved for:
  • Life‑threatening obstruction unresponsive to conservative measures.
  • Diagnostic uncertainty when malignancy cannot be excluded.
  Complete excision is rarely possible because the disease often involves extensive mesenteric tissue.

Supportive & lifestyle measures

• Small, frequent meals to reduce post‑prandial pain.
• Nutrition optimization (high‑protein, low‑fat diet) to counteract weight loss.
• Adequate hydration.
• Smoking cessation and moderation of alcohol intake.
• Regular physical activity as tolerated; gentle walking improves gut motility.

Living with Yamada disease (idiopathic sclerosing mesenteritis)

Because ISM is chronic and often relapsing, patients benefit from a proactive, multidisciplinary approach.

• Follow‑up schedule: Imaging (CT or MRI) every 6–12 months or sooner if symptoms change. Labs (CBC, ESR/CRP) at each visit.
• Medication adherence: Keep a medication diary; use pill organizers to avoid missed doses, especially during tapering of steroids.
• Symptom diary: Record pain intensity, meal timing, bowel habits, and weight. Patterns help the clinician adjust therapy.
• Nutrition support: Consider referral to a registered dietitian for high‑calorie, easy‑to‑digest meals (e.g., smoothies, soups).
• Psychosocial care: Chronic abdominal pain can cause anxiety or depression. Counseling or support groups are valuable.
• Vaccinations: If on long‑term immunosuppression, stay up to date with influenza, pneumococcal, and COVID‑19 vaccines (per CDC guidance).

Prevention

Because the exact cause is unknown, primary prevention is limited. However, modifiable risk factors can be addressed:

• Maintain a healthy weight and balanced diet to reduce chronic inflammation.
• Avoid smoking and limit alcohol consumption.
• Promptly treat intra‑abdominal infections and seek early care for postoperative complications.
• For patients with autoimmune disease, adhere to prescribed disease‑modifying therapy to keep systemic inflammation low.

Complications

If left untreated or poorly controlled, ISM may lead to:

• Intestinal obstruction: Progressive fibrosis can encase bowel loops, causing acute or chronic blockage.
• Ischemia: Compression of mesenteric vessels may reduce blood flow, resulting in ischemic pain or, rarely, infarction.
• Malnutrition and cachexia: Due to chronic pain, early satiety, and malabsorption.
• Secondary infections: Especially in patients receiving high‑dose steroids or biologics.
• Diagnostic uncertainty: Persistent suspicion of malignancy may lead to unnecessary invasive procedures.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe abdominal pain that does not improve with usual pain medication.
• Vomiting that contains blood or looks like coffee grounds.
• Inability to pass gas or stool accompanied by abdominal distention (possible obstruction).
• Fever > 38.5 °C (101.3 °F) with chills, especially if accompanied by worsening pain.
• Rapid heart rate (> 120 bpm), low blood pressure, or signs of shock (dizziness, fainting).
• Sudden, unexplained weight loss > 10 % of body weight in a few weeks.

Prompt evaluation can prevent serious outcomes such as bowel perforation or ischemia.

---

References

1. Kim Y, et al. “Incidental sclerosing mesenteritis on abdominal CT: prevalence and clinical significance.” Radiology. 2020;295(2):456‑464.
2. Ferguson S, et al. “Mesenteric panniculitis: a review of 528 cases.” World J Gastroenterol. 2016;22(33):7546‑7553.
3. Van Den Berg R, et al. “Immunopathology of idiopathic sclerosing mesenteritis.” Ann Surg. 2018;267(5):928‑934.
4. Durst ST, et al. “Sclerosing mesenteritis after abdominal surgery.” Surg Endosc. 2019;33(8):2682‑2688.
5. Parikh N, et al. “Paraneoplastic sclerosing mesenteritis: association with gastrointestinal malignancies.” J Clin Gastroenterol. 2021;55(7):564‑570.
6. Miller FH, et al. “CT features differentiating mesenteric panniculitis from malignancy.” AJR Am J Roentgenol. 2017;209(3):560‑566.
7. Geller DE, et al. “Corticosteroid therapy for idiopathic sclerosing mesenteritis: a multicenter retrospective study.” Clin Gastroenterol Hepatol. 2022;20(4):904‑912.

```